^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Colorectal Cancer
    Drug:Xpovio (selinexor) (XPO1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

    Excerpt:
    ...- KRAS mutant (at least 50 percent [%] of patients): 1-2 prior lines of systemic treatments....
    Trial ID:
    SPRINT
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2022
    Title:

    5519 - Selinexor synergizes with anti-PD-1 antibody and inhibits tumor growth and metastasis in syngeneic mouse models of KRAS mutant colorectal cancer

    Published date:
    03/09/2022
    Excerpt:
    Both selinexor and RMP1-14 demonstrated single agent activity against KRAS mutant CRC in the two mouse models relative to controls.